# Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients With Solid Tumors

> **NCT00942799** · PHASE1 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 87 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Genz-644282 (28-day dosing schedule)
- **DRUG:** Genz-644282 (21-day dosing schedule)

## Key facts

- **NCT ID:** NCT00942799
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2014-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00942799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00942799, "Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients With Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00942799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*